Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model

Gynecologic Oncology

Volumn 141, Issue 2, 2016, Pages 357-363

  Smith, Judith A ^a,b   Mathew, Lata ^a   Burney, Maryam ^a   Nyshadham, Pranavanand ^a   Coleman, Robert L ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bioequivalence; Doxil; Doxorubicin; Lipodox; Liposomal; Microdialysis; Ovarian cancer

Indexed keywords

DOXORUBICIN; GENERIC DRUG; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MODEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; EVALUATION STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICRODIALYSIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PHARMACODYNAMIC PARAMETERS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG SCREENING; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; RANDOMIZATION; THERAPEUTIC EQUIVALENCE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; THERAPEUTIC EQUIVALENCY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960830708     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.02.033     Document Type: Article

References (15)

1. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, and et al. Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
2. R.H. Blum, and S.K. Carter Adriamycin. A new anticancer drug with significant clinical activity Ann. Intern. Med. 80 1974 149 159
3. J.T. Thigpen, C.A. Aghajanian, D.S. Albert, S.M. Campos, A.N. Gordon, M. Markman, D.S. McMeekin, B.J. Monk, and P.G. Rose Role of pegylated liposomal doxorubicin in ovarian cancer Gynecol. Oncol. 96 2005 10 18
4. F.M. Muggia, J.D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, M. Tan, and et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J. Clin. Oncol. 15 1997 987 993
5. A.N. Gordon, J.T. Fleagle, D. Gutherie, and et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 15 2001 3312 3322
6. G.J.R. Charrois, and T.M. Allen Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal formulations in murine breast cancer Biochim. Biophys. Acta 1663 2004 167 177
7. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 5 2003 419 436
8. J.X. Cui, C.L. Li, W.M. Guo, Y.H. Li, C.X. Want, L. Zhang, L. Zhang, Hao YL, and Wang YL Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J. Control. Release 118 2007 204 215
9. R.N.V.S. Mamidi, S. Weng, S. Stellar, C. Wang, N. Yu, T. Huang, A.P. Tonelli, M.F. Kelley, A. Angiuoli, and M.C. Fung Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemother. Pharmacol. 66 2010 1173 1184
10. J.A. Smith, A.B. Costales, M. Jaffari, D.L. Urbauer, M. Frumovitz, C.K. Kutac, H.T. Tran, and R.L. Coleman Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment J. Pharm. Pract. 2015 10.1177/1078155294415
11. FDA News Release FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm337872.htm (accessed 9/30/13)
12. H.H. Chou, K.L. Wang, C.A. Chen, L.H. Wei, C.H. Lai, C.Y. Hsieh, Y.C. Yang, N.F. Two, T.C. Chang, and M.S. Yen Pegylated liposomal doxorubicin (Lipodox®) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow up Gynecol. Oncol. 101 2006 423 428
13. N. Khemapech, S. Oranratanaphan, W. Termrungruanglert, R. Lertkhachonsuk, and A. Vasurattana Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with carboplatin and disteroylphosphtidycholine pegylated liposomal doxorubicin (Lipodox®) Asian Pac. J. Cancer Prev. 14 3 2013 2131 2135
14. P. Power, G. Stuart, A. Oza, D. Provencher, J.R. Bently, W.H. Miller, and J.F. Pouliot Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study Gynecol. Oncol. 114 2009 410 414
15. D.S. Alberts, P.Y. Liu, S.P. Wilczynski, M.C. Clouser, A.M. Lopez, D.P. Michelin, V.J. Lanzotti, and M. Markman Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian cancer or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200) Gynecol. Oncol. 108 2008 90 94